Tag Archive for: STC-15

STORM Therapeutics to present new data on its lead program STC-15 at the 34th EORTC-NCI-AACR Symposium and the 37th SITC Meeting

/in

 STC-15 is an oral small molecule inhibitor of the RNA methyltransferase METTL3  STORM’s first-in-class lead program to enter clinical development in solid tumors in 2022  20 October 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is […]

Read more

Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

/in

STORM recognised as an innovative early-stage biotechnology company pioneering novel drug targets 12 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes for oncology and other diseases, is pleased to announce that Fierce Biotech has named it as one of its 2022 “Fierce 15”, designating […]

Read more

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

/in

7 September 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director. Read more…

Read more
© Optimum Strategic Communications.